Tech Company Financing Transactions

Milestone Pharmaceuticals Funding Round

On 7/26/2017, Milestone Pharmaceuticals announced $55 million in Series C funding from Novo Ventures, BDC Venture Capital and Domain Associates.

Transaction Overview

Company Name
Milestone Pharmaceuticals
Announced On
7/26/2017
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors

Novo Ventures (Lead Investor) (Nilesh Kumar)

BDC Venture Capital

Domain Associates

Fonds de solidarite FTQ

Forbion Capital Partners (Marco Boorsma)

GO Capital

Pappas Ventures

Tekla Capital Management (Daniel Omstead)

Proceeds Purpose
The company intends to use the funds to advance etripamil, its lead product, into Phase 3 development including the execution of pivotal and supportive clinical trials, the production of clinical and commercial supplies and pre-launch commercialization activities, to expand its resources including select additional headcount and advisory support in strategic areas including Marketing and Medical Affairs.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1111 Dr.-Frederik-Philips Blvd. 420
Saint-Laurent QC, H4M 2X6
Canada
Phone
(514) 336-0444
Website
www.milestonepharma.com
Email Address
[email protected]
Overview
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions.
Profile
Milestone Pharmaceuticals LinkedIn Company Profile
Social Media
Milestone Pharmaceuticals Company Twitter Account
Company News
Milestone Pharmaceuticals News
Facebook
Milestone Pharmaceuticals on Facebook
YouTube
Milestone Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Joseph Oliveto
  Joseph Oliveto LinkedIn Profile  Joseph Oliveto Twitter Account  Joseph Oliveto News  Joseph Oliveto on Facebook
Chief Medical Officer
Francis Plat
  Francis Plat LinkedIn Profile  Francis Plat Twitter Account  Francis Plat News  Francis Plat on Facebook
Vice President
Jeffrey Nelson
  Jeffrey Nelson LinkedIn Profile  Jeffrey Nelson Twitter Account  Jeffrey Nelson News  Jeffrey Nelson on Facebook
Vice President
Douglas Wight
  Douglas Wight LinkedIn Profile  Douglas Wight Twitter Account  Douglas Wight News  Douglas Wight on Facebook
VP - Bus. Development
Lorenz Muller
  Lorenz Muller LinkedIn Profile  Lorenz Muller Twitter Account  Lorenz Muller News  Lorenz Muller on Facebook
VP - Manufacturing
Harish Pimplaskar
  Harish Pimplaskar LinkedIn Profile  Harish Pimplaskar Twitter Account  Harish Pimplaskar News  Harish Pimplaskar on Facebook
VP - Regulatory Affairs
Guy Rousseau
  Guy Rousseau LinkedIn Profile  Guy Rousseau Twitter Account  Guy Rousseau News  Guy Rousseau on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/26/2017: Sebacia venture capital transaction
Next: 7/26/2017: Vicarious venture capital transaction

 

Share this article

 

About Database of VC Transactions

We record funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.